Biosimilar Antibodies

Tecaginlimab (BNT-312) is an Fc-inert bispecific antibody engineered for the dual targeting and conditional stimulation of CD40 and 4-1BB receptors. This antibody is designed to enhance the priming and reactivation of tumor-specific immune responses, making it a valuable tool for research in cancer immunotherapy. Tecaginlimab's unique ability to engage both CD40 and 4-1BB under specific conditions allows for precise modulation of immune activation, potentially leading to improved therapeutic outcomes in oncology research.

Robatumumab (Sch 717454) is a monoclonal antibody targeting the insulin-like growth factor receptor-1 (IGF-1R). It exhibits potent anti-tumor and anti-proliferative effects on cancer cells. This antibody is particularly relevant for research in osteosarcoma and Ewing sarcoma, providing a valuable tool for investigating the role of IGF-1R in cancer pathogenesis and therapy.

The Anti-TLR3/CD283 Antibody (CNTO5429) is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets TLR3/CD283, a receptor involved in the innate immune response to viral double-stranded RNA. This antibody comprises a human IgG2 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145.42 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa.

Vulinacimab (HLX-06) is a monoclonal antibody targeting VEGFR-2, a receptor overexpressed in various tumor types. This antibody is instrumental in studying the mechanisms of angiogenesis and the associated processes of proliferation, survival, migration, and differentiation of endothelial cells in cancer research. Vulinacimab provides a valuable tool for investigating the role of VEGFR-2 in oncological pathologies and therapeutic interventions.

Emfizatamab is a monoclonal antibody designed to target CD19, CD3E, TNFRSF9, and PD-L1. This multifunctional antibody facilitates the engagement of immune effector cells with cancer cells, potentially enhancing the immune response against malignant cells. It is primarily used in research focused on the mechanisms of immune modulation in oncology and the therapeutic potential in various cancers.

Burosumab is a human monoclonal antibody that selectively neutralizes fibroblast growth factor 23 (FGF23). This antibody is employed in the study of disorders such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia, offering significant insights into the pathophysiological mechanisms and potential therapeutic targets for these conditions.

Siltartoxatug is a human monoclonal antibody of the IgG1κ subtype, specifically designed to target tetanus toxin. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

PY314 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Triggering Receptor Expressed on Myeloid cells 2 (TREM2). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), offering potential applications in targeted cancer therapy.

Anti-E-Selectin Antibody (CL2) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, specifically designed to target human E-Selectin. For accurate isotype control in experimental procedures, it is recommended to use Mouse IgG2a kappa Isotype Control. This antibody is ideal for researchers studying cellular adhesion processes, inflammation, and vascular biology.

The Anti-Matriptase Antibody is a human-derived monoclonal antibody, expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting Matriptase. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control serves as the appropriate isotype control for this antibody. This product is ideal for research applications focusing on the biological role and pathological significance of Matriptase.

MB-66 (MAPP-66) is a fully human IgG1 monoclonal antibody designed for vaginal application, specifically targeting HSV (Herpes Simplex Virus) and HIV (Human Immunodeficiency Virus). This product is presented as a monoclonal antibody film, optimizing local delivery and bioavailability at the site of viral entry. For experimental controls, MB-66 utilizes Human IgG1 kappa as its isotype control, ensuring specificity and reliability in research applications.

Ranibizumab (RG-6321), a humanized monoclonal antibody fragment, targets and inhibits vascular endothelial growth factor A (VEGF-A), recognizing all its isoforms including VEGF110, VEGF121, and VEGF165. This anti-VEGF agent is effective in slowing vision loss in vivo and is primarily utilized in research focused on wet age-related macular degeneration (AMD).

Romosozumab is a humanized monoclonal antibody that targets sclerostin, a protein involved in the regulation of bone metabolism. By inhibiting sclerostin, Romosozumab enhances bone formation and decreases bone resorption, making it a valuable tool for investigating the pathophysiology and potential treatments of osteoporosis. This antibody is specifically designed for use in research applications focused on bone density disorders and related metabolic bone diseases.

Atoltivimab (REGN3470), also known as maftivimab/odesivimab under the brand name Inmazeb, is distinguished as the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for targeting Zaire ebolavirus (EBOV) infections. This therapeutic agent is specifically designed to neutralize the virus, providing a critical tool in the management and treatment of Ebola virus disease.

The Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonal antibody specifically designed to target Dectin-1, a key receptor involved in the recognition of β-glucans on pathogens, thereby playing a crucial role in the immune response against fungal infections. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is ideal for use in research focused on immune system responses, particularly in the study of fungal pathogenesis and innate immunity.

Lodapolimab (LY3300054) is an IgGλ monoclonal antibody that targets the programmed cell death protein 1 (PD-1). This antibody is designed to inhibit the PD-1 signaling pathway, which may enhance the immune system's ability to fight cancer.

Olendalizumab (ALXN1007) is a humanized monoclonal antibody derived from mouse IgG2-G4-κ, specifically designed to target Complement protein C5a with a dissociation constant (Ki) of 60 pM. This antibody plays a crucial role in modulating the complement inflammatory pathway. Olendalizumab is primarily utilized in research focused on complement-mediated disorders, particularly those associated with coronavirus infections. This specificity and application make it a valuable tool for studies aimed at understanding and potentially mitigating the impact of complement system dysregulation in viral diseases.

Bectumomab (IMMU-LL 2) is a humanized IgG2a monoclonal antibody specifically targeting human CD22, an antigen predominantly expressed on the surface of B cells. This antibody is engineered as an anti-lymphoma agent, primarily utilized in the detection and management of non-Hodgkin's lymphoma (NHL). Bectumomab is compatible for use in imaging studies when conjugated with technetium-99 (Tc99m LL2 Fab), facilitating the assessment of lymphoma staging in both recurrent and newly diagnosed cases. Additionally, it serves as a valuable tool in evaluating the efficacy of targeting prior to the initiation of radioimmunotherapy (RIT). This antibody's specificity and application in advanced diagnostic imaging and therapy make it a critical component in lymphoma research and clinical practice.

Prolgolimab (BCD-100) is a human IgG1 monoclonal antibody targeting the PD-1 receptor, incorporating an Fc region modified with the 'LALA' mutation to silence effector functions. This antibody is utilized in research focused on advanced melanoma, providing a valuable tool for investigating the immunological pathways involved in tumor progression and response to therapy.

The Anti-FOLR1/FRA Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the FOLR1/FRA protein. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 146.46 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is applicable for use in various immunological assays to study the role and expression of the FOLR1/FRA protein in biological systems.

Elsilimomab (B-E8) is an IgG1 monoclonal antibody that targets interleukin-6 (IL-6), exhibiting a dissociation constant (KD) of 22 pM and an inhibitory concentration (IC50) of 1.4 nM. This antibody is utilized in research focused on multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA), providing a valuable tool for investigating the role of IL-6 in these conditions.

Pasritamig is a bispecific antibody designed to target KLK2 and CD3E. It is structured as a (H-γ1_L-κ)_scFvkh-G1(h-CH2-CH3) type, combining specificity to both antigens. This configuration enhances its application in directing immune system components to tumor cells expressing KLK2, thereby facilitating targeted immunotherapy. Pasritamig is primarily used in research focused on cancer therapy modalities, particularly in studies investigating prostate cancer and immune cell engagement mechanisms.

PF-5212374 (TRU-015) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD20 (MS4A1). This antibody features a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with a molecular weight of approximately 145 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Tegoprubart is a monoclonal antibody specifically targeting the CD40 ligand (CD40L), an essential component of immune system costimulation. By inhibiting CD40L, Tegoprubart effectively diminishes both cellular and antibody-mediated immune responses, facilitating the creation of a more tolerant immune environment. This antibody has demonstrated significant in vivo efficacy in various transplantation animal models, underscoring its potential utility in immune modulation and transplant medicine.

Lirilumab (IPH2102) is a monoclonal antibody targeting KIR (Killer-cell Immunoglobulin-like Receptors), demonstrating significant antitumor activity. This antibody is specifically designed for research applications focusing on leukemia and squamous cell carcinoma of the head and neck (SCCHN), providing a valuable tool for studies aimed at understanding and potentially modulating immune responses in these cancers.

Ruxoprubart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target complement factor B (CFB). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

XmAb 5592 is a humanized, Fc-engineered monoclonal antibody targeting HM1.24, designed to enhance binding affinity to FcγRIIIa and FcγRIIa receptors. This antibody facilitates increased lysis of HM1.24-specific multiple myeloma (MM) cells through both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in vitro. This specificity and mechanism of action make XmAb 5592 a valuable tool for research into therapeutic interventions for multiple myeloma.

Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody designed to target integrin αIIbβ3. It exhibits potent antiplatelet and antithrombotic properties, making it an ideal candidate for research into cardiovascular diseases. Tadocizumab's specificity for integrin αIIbβ3 allows for the study of this integrin's role in platelet aggregation and thrombus formation, providing valuable insights into potential therapeutic approaches for thrombotic disorders.

Labetuzumab is a humanized monoclonal antibody targeting the carcinoembryonic antigen (CEA), known for its role in inhibiting tumor growth. This antibody has demonstrated efficacy in sensitizing human medullary thyroid cancer xenografts to Dacarbazine, enhancing the chemotherapeutic response. Labetuzumab is utilized primarily in research focused on the treatment and mechanistic understanding of cancer progression and therapy resistance.

Panitumumab (ABX-EGF) is a fully human IgG2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), exhibiting potent anti-tumor properties. This antibody effectively inhibits tumor cell proliferation, survival, and angiogenesis, making it a valuable tool for cancer research, particularly in studies focused on colon cancer.

Datopotamab (CDP7657) is a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), particularly when conjugated with the DNA topoisomerase I inhibitor, Deruxtecan. Datopotamab is primarily utilized in research focused on triple-negative breast cancer and non-small cell lung cancer, providing a valuable tool for investigating therapeutic avenues in these challenging oncological contexts.

The Anti-ANO1/TMEM16A Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target ANO1/TMEM16A, a calcium-activated chloride channel implicated in various physiological processes. This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control, it is recommended to use Human IgG1 kappa, Isotype Control, to aid in distinguishing specific from non-specific binding.

The Anti-Orai1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Orai1 protein. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, with an approximate molecular weight of 150 kDa. For isotype control, the Human IgG2 kappa, Isotype Control is recommended. This product is essential for studies focusing on the role of Orai1 in calcium channel function and its implications in immune response and various cellular processes.

The Anti-CXC-ELR Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CXC-ELR motif. This antibody is composed of a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For use as an isotype control, the Human IgG4 kappa, Isotype Control is recommended. This product is ideal for research applications requiring precise targeting of the CXC-ELR motif.

Inlecitug is a chimeric monoclonal antibody designed to target the human kinase insert domain receptor (KDR). By specifically binding to KDR, Inlecitug effectively blocks the interaction between vascular endothelial growth factor (VEGF) and KDR, subsequently inhibiting angiogenesis. This inhibition plays a crucial role in exerting antitumor activity, making Inlecitug a valuable tool for cancer research.

The Anti-TNFSF9/4-1BBL Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells that specifically targets TNFSF9, also known as 4-1BBL. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, researchers should use the Human IgG1 kappa, Isotype Control. This antibody is ideal for studies focusing on the biological activities and interactions of TNFSF9/4-1BBL in immune regulation and cancer immunotherapy research.

Vamikibart is a chimeric humanized monoclonal antibody of the IgG2κ isotype, specifically designed to target interleukin 6 (IL-6). This antibody is engineered for high specificity and affinity in neutralizing IL-6, a cytokine involved in various inflammatory and autoimmune processes. Vamikibart is suitable for use in research focused on the role of IL-6 in disease mechanisms and therapeutic interventions.

Mavrostobart is a human monoclonal antibody of the IgG4κ isotype that specifically targets NT5E (CD73). For experimental control purposes, the recommended isotype control is Human IgG4 (S228P) kappa. This antibody is designed for precise binding to NT5E, making it highly relevant for research into its role in immunoregulation and tumor progression.

The Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody specifically designed to target the c-Met receptor, also known as hepatocyte growth factor receptor (HGFR). This antibody is recommended for use with Human IgG1 kappa as an isotype control to ensure specificity and accuracy in experimental results.

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k monoclonal antibody designed to specifically target mesothelin (MSLN), a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein. Mesothelin is expressed in a limited range of normal adult tissues, predominantly in the mesothelium. This antibody binds to the cell surface mesothelin, making it a valuable tool for research into mesothelin's role in various biological processes and diseases.

Cedelizumab (RWJ 49004) is an IgG4 monoclonal antibody designed to specifically target CD4, a glycoprotein expressed on the surface of immune cells such as T helper cells. This antibody exhibits immunosuppressive properties, making it a valuable tool for research into immune response modulation and potential therapeutic applications in autoimmune diseases and transplant rejection.

MK-4166 is a humanized IgG1 monoclonal antibody designed as an agonist targeting the glucocorticoid-induced TNFR-related protein (GITR). This antibody facilitates the enhancement of proliferation in both naïve and tumor-infiltrating T lymphocytes, making it a critical tool in the study of T cell dynamics and cancer immunotherapy. MK-4166's specificity for GITR and its agonistic properties position it as a valuable agent for research focused on immune response modulation within oncological environments.

Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody designed to specifically target the insulin-like growth factor 1 receptor (IGF-1R). This antibody functions by inhibiting the signaling pathways initiated by IGF-1 and IGF-2, which are commonly implicated in tumor cell proliferation. It effectively blocks IGF-1R autophosphorylation and subsequent phosphorylation of Akt, a critical node in the pro-survival signaling network. Additionally, Dalotuzumab promotes apoptosis and induces cell cycle arrest, further inhibiting cancer cell growth. Research has demonstrated that when used in conjunction with other anticancer agents, including statins, Dalotuzumab exhibits enhanced antitumor efficacy both in vitro and in vivo. This makes it a valuable tool for studies focused on cancer biology and therapeutic antibody development.

Exbivirumab is a monoclonal antibody specifically targeting the hepatitis B virus (HBV). This antibody is designed to augment the antiviral efficacy of hepatitis B immunoglobulin (HBIG), providing a potentiated response against HBV infections. Exbivirumab is pivotal in research focused on the development of more effective therapeutic protocols for hepatitis B, offering a promising tool for both basic research and clinical applications.

Lesofavumab (MHAB5553A) is a humanized IgG1κ monoclonal antibody specifically targeting the influenza B virus. This antibody is designed for high specificity and affinity in binding to influenza B antigens, making it an essential tool for research focused on viral pathogenesis, immune response, and potential therapeutic interventions for influenza B infections.

Recibokibart is a humanized IgG1κ monoclonal antibody specifically targeting IL1RL2. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Navenibart is a humanized IgG1κ monoclonal antibody specifically targeting KLKB1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.